Hepatitis A (HAV) produces a self-limiting liver disease which can produce a range of symptoms such as nausea, anorexia, fever, malaise or abdominal pain. Unlike Hepatitis B and C viruses it does not cause a long term chronic infection although it can manifest itself as prolonged or relapsing disease for up to six months. The HAV virus is transmitted by person-to-person transmission through the fecal-oral route sometimes in outbreaks to due ingestion of contaminated food. Many countries in Africa, LATAM and SE Asia have high or intermediate endemnicity for HAV.
The Hepatitis A vaccine is highly effective at preventing HAV infection and is now recommended for all children at age 1 year in the United States and other selected countries which have added the vaccine as part of a national immunization program (NIP). The HAV vaccine is also widely used in the travelling population to high or intermediate endemic countries.
This MarketVIEW is a comprehensive commercial opportunity assessment which forecasts the potential (value/volume) of monovalent HAV vaccines in the travelling population from EU, North Amercia and selected ROWD countries of origin. The model uses a "build up" methodology based upon number of trips to HAV endemic countries forecasted to 2030. It is designed to compliment other VacZine Analytics analyses focused on HAV vaccines..
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 1 MODEL